Pneumococcal conjugate second or third-dose vaccines (PCVc) in Norway
Norway: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 95.0% in 2025. ▲ Rising
Latest (2025)
95.0%
Change on year
unchanged
World rank
38th
of 194 countries
All-time high
96.0%
in 2020
All-time low
86.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Norway, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Norway stood at 95.0%.
That represents a change of up 2.2% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Norway peaked at 96.0% in 2020 and was at its lowest, 86.0%, in 2008.
That places Norway 38th out of 194 countries with data for 2025, putting it in the top quarter.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Norway, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 86.0% | — |
| 2009 | 91.0% | +5.8% |
| 2010 | 91.0% | +0.0% |
| 2011 | 92.0% | +1.1% |
| 2012 | 93.0% | +1.1% |
| 2013 | 93.0% | +0.0% |
| 2014 | 91.0% | -2.2% |
| 2015 | 93.0% | +2.2% |
| 2016 | 94.0% | +1.1% |
| 2017 | 94.0% | +0.0% |
| 2018 | 94.0% | +0.0% |
| 2019 | 95.0% | +1.1% |
| 2020 | 96.0% | +1.1% |
| 2021 | 96.0% | +0.0% |
| 2022 | 95.0% | -1.0% |
| 2023 | 95.0% | +0.0% |
| 2024 | 95.0% | +0.0% |
| 2025 | 95.0% | +0.0% |
Norway compared with similar countries
- Norway's 95.0% is above the median for high income countries, which is 91.0%, 1.0× the median. (63 countries reporting)
- Norway's 95.0% is above the median for Europe & Central Asia, which is 87.0%, 1.1× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 88.5% | 86.0% | 91.0% | 2 |
| 2010s | 93.0% | 91.0% | 95.0% | 10 |
| 2020s | 95.3% | 95.0% | 96.0% | 6 |
Countries ranked near Norway
More health data for Norway
- Un projection of annual infant deaths, annual growth rate -7.69 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.337 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,212 deaths per 1,000 people (2090)
- Number of infants who die before age 1 12 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2021)
- Population ages 00-04, female, annual growth rate -0.217 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0238 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.0617 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Norway?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Norway was 95.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Norway?
- The highest recorded value was 96.0% in 2020.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Norway?
- The lowest recorded value was 86.0% in 2008.
- How does Norway rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Norway ranks 38th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Norway?
- Over the last ten years it is up 2.2%. The long-run trend across the full record is rising.
- Where does this Norway data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).